FABP2 and serum lipopolysaccharide activity: Secondary and exploratory outcomes include clinical disease activity, systemic inflammation (e.g., IL-10), intestinal permeability (e.g., intestinal fatty acid binding protein) and endotoxemia (e.g., LPS), platelet function, stool microbiome and bile acid composition, and the metabolic profile of XN in humans over 8 weeks.